Searchable abstracts of presentations at key conferences in endocrinology

ea0021p213 | Endocrine tumours and neoplasia | SFEBES2009

Concordance between thyroglobulin antibody assays

Parkington Damon , Littleboy Sonia , Taylor Kevin , Jeffries Sarah , Simpson Helen , Halsall David

As thyroglobulin antibodies (TgAb) are a well recognised cause of interference in thyroglobulin (Tg) immunoassays current guidelines recommend that TgAb should be measured concurrently with Tg when monitoring thyroidectomised thyroid cancer patients. However the concordance between different TgAb assays has been questioned despite the availability of an International TgAb Reference Preparation (MRC 65/93).Four commonly used TgAb assays were tested in 145...

ea0021p204 | Endocrine tumours and neoplasia | SFEBES2009

Temozolomide-induced regression of hepatic metastases in a pituitary corticotroph carcinoma with low O6-methylguanine-DNA methyltransferase expression

Burton Hannah , Annamalai Anand K , Dean Andrew , Kovacs Kalman , Antoun Nagui , Kirollos Ramez W , Simpson Helen L , Jeffries Sarah J , Burnet Neil G , Gurnell Mark

Background: Pituitary carcinoma occurs in ~0.2% of resected pituitary tumours, and carries a poor prognosis (mean survival <4 years), with standard chemotherapeutic regimens showing limited efficacy. However, recent evidence suggests that temozolomide, an orally active alkylating agent used principally in the management of glioblastoma, may also be effective in controlling aggressive/invasive pituitary adenomas/carcinomas. Low levels of expression of the DNA-repair enzyme ...